Business
Catheter Precision Announces Strategic Sale of Non-Core Assets to Strengthen Balance Sheet and Accelerate Electrophysiology Growth
Upfront Cash, Equity Participation and Tiered Royalty Structure Providing Long-Term Revenue UpsideFORT MILL, S.C., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a leader in advanced electrophysiology solutions, today announced it has entered into a definitive agreement to divest its atherectomy catheter technologies, including associated FDA approvals and patents, to a strategic acquirer. Following a comprehensive portfolio review, the Company determined that
About this update from Catheter Precision, Inc.
[{"type":"image","alt":"Catheter Precision, Inc.","displaySize":"","headline":null,"caption":"Catheter Precision, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":274,"height":58,"url":"https://media.zenfs.com/en/globenewswire.com/c0002fcea5abba0697310d2b7733beb5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YQBzazT126278wVP0b5CKA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg5O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/c0002fcea5abba0697310d2b7733beb5","width":274,"height":58}},"lazy":false},{"type":"text","content":"Upfront Cash, Equity Participation and Tiered Royalty Structure Providing Long-Term Revenue Upside","length":98,"tagName":"p"},{"type":"text","content":"FORT MILL, S.C., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a leader in advanced electrophysiology solutions, today announced it has entered into a definitive agreement to divest its atherectomy catheter technologies, including associated FDA approvals and patents, to a strategic acquirer.","length":335,"tagName":"p"},{"type":"text","content":"Following a comprehensive portfolio review, the Company determined that monetizing these non-core assets enhances capital efficiency and sharpens focus on its high-growth electrophysiology platform.","length":198,"tagName":"p"},{"type":"text","content":"Strategic Rationale","length":19,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Focus our capital allocation on core cardiac arrhythmia technologies","length":68,"tagName":"p"}]},{"val":[{"type":"text","content":"Strengthened balance sheet","length":26,"tagName":"p"}]},{"val":[{"type":"text","content":"Simplified operating structure with enhanced strategic clarity","length":62,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":156,"olType":false},{"type":"text","content":"Transaction Highlights","length":22,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Upfront cash payment following closing of $15,000","length":49,"tagName":"p"}]},{"val":[{"type":"text","content":"A 5% equity stake in the acquiring company with anti-dilution protection up to $5 million of additional equity capital being invested in the acquiring company","length":158,"tagName":"p"}]},{"val":[{"type":"text","content":"Ten-year royalty payments agreement on net sales:","length":49,"tagName":...